Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate – CEPI
CEPI to provide up to $328m for development of Clover's Covid-19 vaccine
Clover Biopharmaceuticals | Science | Trimer-Tag™
CEPI expands Covid-19 vaccine alliance with Clover Biopharmaceuticals - Pharmaceutical Technology
Clover | Science | Trimer-Tag™ Oncology
Clover Biopharmaceuticals Becomes the 9th Enterprise in CDHT Listed on the Hong Kong Stock Exchange_News_GaoxinEnglish
Clover and Dynavax initiate dosing in Covid-19 vaccine candidate trial
Clover Biopharma nabs $250M-plus for COVID-19 vaccine in expanded CEPI deal | Fierce Biotech
PharmaBoardroom - China's Clover Biopharmaceuticals Partners with GSK on COVID-19 Vaccine
Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients | Business Wire
CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI
Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern
Clover | Science | Trimer-Tag™ Oncology
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
Clover Bio Dumps GSK Adjuvant Technology, Will Take Dynavax to Vaccine Dance | BioSpace
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
Clover nears pivotal trial of GSK-adjuvanted COVID-19 vaccine | Fierce Biotech
Clover Biopharmaceuticals | Science | Trimer-Tag™
China's Clover generates US$230m in funding as its COVID-19 vaccine candidate edges towards late stage clinical trial
Clover Biopharmaceuticals: Phase 1 COVID-19 Vaccine Results - Infectious Disease Advisor
